Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | CLK3 | P49761 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26100602 | 1.00 | ABL1 (0.56) | ABL1LMNACYP11B1CYP11B2MAP4K1 | |
| SCHEMBL26463431 | 0.76 | ABL1 (0.52) | ABL1CYP11B1CYP11B2MAP4K1PDGFRA | |
| SCHEMBL30494494 | 0.76 | ABL1 (0.52) | ABL1CYP11B1CYP11B2MAP4K1PDGFRA | |
| SCHEMBL26463643 | 0.76 | CYP11B1 (0.55) | ABL1CYP11B1CYP11B2MAP4K1CLK2 | |
| SCHEMBL30494300 | 0.76 | CYP11B1 (0.55) | ABL1CYP11B1CYP11B2MAP4K1CLK2 | |
| SCHEMBL130615 | 0.76 | LMNA (0.65) | ABL1LMNADYRK1AIRAK4 | |
| SCHEMBL5345714 | 0.73 | LMNA (0.65) | LMNADYRK1A | |
| SCHEMBL1621800 | 0.72 | ABL1 (1.00) | ABL1PDGFRAKIT | |
| SCHEMBL9678587 | 0.72 | ALDH1A1 (0.69) | ABL1LMNA | |
| SCHEMBL9893073 | 0.72 | LMNA (0.63) | ABL1LMNADYRK1AIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236613-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-07-24 | — | — | US | disclosed |
| EP-4423067-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-09-04 | — | — | EP | disclosed |
| CN-118176181-A | SARM1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023072026-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236613-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SARM1, ADRM1, SMN1; SMN2 | ABL1 4640/4885LMNA 1025/4885CYP11B1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.